Biomarker testing in advanced non-small cell lung cancer is being optimized to expand targeted treatment options. The process involves selecting the optimal agent for frontline treatment and may include reflex testing to close molecular testing gaps. The role of biomarker testing and targeted therapy is also being explored in various contexts, including early-stage disease and in combination with other treatments such as immunotherapy and radiotherapy.